EU/3/19/2232: Orphan designation for the treatment of amyotrophic lateral sclerosis

Lactobacillus plantarum


On 16 December 2019, orphan designation EU/3/19/2232 was granted by the European Commission to MDC RegAffairs GmbH, Germany, for Lactobacillus plantarum for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
Lactobacillus plantarum
Intended use
Treatment of amyotrophic lateral sclerosis
Orphan designation status
EU designation number
Date of designation

MDC RegAffairs GmbH    
Baumberger Strasse 11  
50737 Cologne 
Tel: +49 (0) 221 7401339

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating